India Pharma in EU: 26% Generic Market Share but Concentrated in 3 Countries

India is the world' largest generic medicine exporter and EU is its most important pharmaceutical export market. But a granular analysis reveals striking geographic concentration that represents both a risk and opportunity.

India EU pharma market share by country: Netherlands: 31% of Dutch generic imports (highest in EU, driven by distribution hub function and Teva Netherlands). Germany: 28% (driven by mandatory generic substitution — GKV-SV). UK: 26% (historical relationship, NHS generic price preference). Belgium: 18%. Italy: 12%. France: 9%. Spain: 8%. Poland: 6%.

Why the concentration exists: Germany, Netherlands, and UK have the most developed generic substitution systems — mandatory generic dispensing at pharmacy or competitive tendering. These systems reward low-cost generic manufacturers — India' competitive strength. France and Spain have more brand-loyal prescription patterns and higher originator medicine preferences.

The opportunity in underrepresented EU markets: Italy (EUR 18B pharmaceutical market), France (EUR 52B), and Spain (EUR 20B) are significantly underpenetrated by Indian generics. Growing generic substitution rates in these markets — driven by healthcare cost pressure — represent a structural tailwind for Indian pharma market share growth in 2026-2030. Indian companies building relationships with Italian, French, and Spanish generic distributors now are positioning for this structural shift.